Moving toward standardization of urine albumin measurements

Jesse C. Seegmiller¹, W. Greg Miller², Lorin M. Bachmann²

¹ University of Minnesota, Department of Laboratory Medicine and Pathology, Minneapolis, Minnesota, USA
² Virginia Commonwealth University, Department of Pathology, Richmond, Virginia, USA

ARTICLE INFO

Corresponding author:
Jesse C. Seegmiller
University of Minnesota
Department of Laboratory Medicine and Pathology
420 Delaware Street S.E.
Minneapolis, MN 55455
United States of America
Phone: 1-612-625-6198
Fax: 1-612-625-4831
E-mail: jseegmil@umn.edu

Key words:
urine albumin, standardization, calibration, reference measurement procedure

ABSTRACT

Measurement of urine albumin is important for detecting and monitoring kidney disease. At the present time, measurement of urine albumin is not standardized due to the lack of a reference system, which includes both a reference measurement procedure and certified reference materials. Developing a reference system will provide a means for clinical laboratory measurement procedures to become standardized and will enable successful use of uniform clinical decision points. Currently, urine albumin results vary in excess of 40% depending on which commercially available measurement procedure is utilized for measurement. Clinicians may struggle with classification of kidney disease in part due to differences in measurements from lack of agreement among laboratory methodologies employed when assessing urine albumin concentrations. This report focuses on current findings in urine albumin testing, highlights important measurement and reporting considerations, and presents strategies for developing a reference measurement procedure to enable standardization of urine albumin measurements.
INTRODUCTION

Urine albumin is a diagnostic and prognostic marker for chronic kidney disease (CKD), diabetes and cardiovascular disease. When interpreting measurements of urine albumin, providers must consider the type of urine collection and the methodology used for analytical measurement. The historical standard for measuring the amount of albumin excreted into the urine, known as the urine albumin excretion rate, has been to measure the albumin concentration obtained from a 24-hour urine collection. In clinical practice, 24-hour urine collections present problems in terms of specimen storage and timing accuracy. Thus, assessment of urine albumin from shorter collection times is a common clinical practice and presents a more convenient collection option. In untimed situations, the urine albumin result should be indexed to urine creatinine concentration and reported as the albumin to creatinine ratio (ACR). The ACR accounts for hydration and produces a ratio that has similar diagnostic performance as a 24-hour urine albumin excretion rate. A caveat to these different timing approaches is differences in classification of albuminuria depending on timing of collection. Therefore, the collection method should remain consistent throughout studies.

Recommendations are to report the ACR along with the albumin concentration, preferably collect the first morning void specimen, and follow-up findings from random urine collections with first morning void collections.

A variety of testing methodologies have been employed to monitor urine albumin including turbidimetry, dipstick, radioimmunoassay, immunoturbidimetry, immunonephelometry, high performance liquid chromatography, liquid chromatography mass spectrometry, and liquid chromatography tandem mass spectrometry (LC-MS/MS).

Some of these methods are known to have issues with analytical specificity when measuring urine albumin. One essential attribute for a reference measurement procedure is that it must be specific for the measurand it is intended to quantify and not be influenced by matrix effects or interfering substances that can be present in patient urine.

This report highlights standardization recommendations for urine albumin measurements and focuses on methodologies likely suitable for use as a reference measurement procedure for standardizing such measurement results.

PREANALYTICAL AND STORAGE CONSIDERATIONS FOR URINE ALBUMIN

Several precollection factors have been shown to increase urine albumin excretion such as exercise, posture and fever. These factors should be considered when assessing albuminuria for comprehensive renal workups. Interventions may not be indicated in patients with the above conditions unless the albuminuria persists when the confounding physiological conditions are no longer present. Nonspecific binding of albumin to urine collection containers does not contribute to measurement error, as binding to the container has been estimated to be <1% depending on the container hydrophobicity, which is considered inconsequential.

A fresh midstream collection for urine albumin measurement is preferred. Albumin can remain stable in urine for up to 8 weeks when stored under refrigerated conditions at 4 °C. For long term frozen storage of urine albumin samples, a temperature -70 °C or lower is required. Degradation of albumin in urine causing measurement issues has been reported when stored at -20 °C over periods of 2 weeks to 3 years. Therefore, careful attention must be paid to the storage conditions for urine specimens particularly for investigations using stored samples.
CURRENT STATE OF URINE ALBUMIN MEASUREMENTS

While the utility of this biomarker is clear, applying disease specific cutoffs for albuminuria becomes compromised near the decision values due to non-standardized measurement procedures used in clinical laboratories. In a study that evaluated the state of agreement among 16 quantitative clinical laboratory immunoassay measurement procedures from in-vitro diagnostics manufacturers, who distribute globally, results from 332 freshly collected non-frozen urine albumin samples had total coefficients of variation (CVs) of 5.2-8.1% and the effects of sample-specific influences were < 10% for most measurement procedures. However, bias was found to cause a significant lack of agreement among measurement procedures. The median difference range for routine measurement procedures vs. a comparator LC-MS/MS procedure was approximately 40%. Mean biases ranged from -35% to +34% for concentrations near 15 mg/L and -15% to +18% for concentrations near 30 mg/L. The results of this study demonstrate that fixed decision thresholds cannot be effectively utilized due to lack of agreement among routine measurement procedures and therefore standardization is needed.

The College of American Pathologists offers an Accuracy Based Urine Survey that uses unaltered pooled frozen human urine as the samples.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Methods</th>
<th>N. Labs</th>
<th>Median, mg/L</th>
<th>Median bias vs. LC-MS/MS, %</th>
<th>Low value, mg/L</th>
<th>High value, mg/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Siemens Dimension Vista (IN)</td>
<td>7</td>
<td>16</td>
<td>-1.8</td>
<td>16</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>Abbott Architect c Systems (IT)</td>
<td>10</td>
<td>13</td>
<td>-20.2</td>
<td>11</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Beckman AU Series (IT)</td>
<td>8</td>
<td>13</td>
<td>-20.2</td>
<td>11</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Roche cobas c500 Series</td>
<td>9</td>
<td>12</td>
<td>-26.4</td>
<td>10</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Vitros 5.1 FS/4600/5600</td>
<td>5</td>
<td>15</td>
<td>-8.0</td>
<td>8</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>All methods</td>
<td>58</td>
<td>13</td>
<td>-20.2</td>
<td>8</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>LC-MS/MS</td>
<td>-</td>
<td>16.3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Siemens Dimension Vista (IN)</td>
<td>Abbott Architect c Systems (IT)</td>
<td>Beckman AU Series (IT)</td>
<td>Roche cobas c500 Series</td>
<td>Vitros 5.1 FS/4600/5600</td>
<td>All methods</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------------</td>
<td>--------------------------------</td>
<td>------------------------</td>
<td>-------------------------</td>
<td>------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>10</td>
<td>7</td>
<td>11</td>
<td>5</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>38</td>
<td>32</td>
<td>31</td>
<td>32</td>
<td>37</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>4.1</td>
<td>-12.3</td>
<td>-15.1</td>
<td>-12.3</td>
<td>1.4</td>
<td>-12.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>25</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>32</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Siemens Dimension Vista (IN)</th>
<th>Abbott Architect c Systems (IT)</th>
<th>Beckman AU Series (IT)</th>
<th>Roche cobas c500 Series</th>
<th>Vitros 5.1 FS/4600/5600</th>
<th>All methods</th>
<th>LC-MS/MS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7</td>
<td>9</td>
<td>7</td>
<td>11</td>
<td>5</td>
<td>58</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>192</td>
<td>164</td>
<td>167</td>
<td>155</td>
<td>166</td>
<td>164</td>
<td>184.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>178</td>
<td>195</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>178</td>
<td>195</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>167</td>
<td>195</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>167</td>
<td>195</td>
</tr>
</tbody>
</table>

* Data used with permission from the College of American Pathologists (IN) - immunonephelometric, (IT) - immunoturbidimetric
Table 1 shows participant results compared to an LC-MS/MS candidate reference measurement procedure. Although there were a small number of participants, the information is representative and consistent with the previously mentioned larger study based on individual patient urine samples. The median bias vs. the comparative method was larger at lower concentrations of urine albumin with the all methods bias -20% at 16 mg/L, -12% at 36 mg/L, and -11% at 184 mg/L. The joint committee of the Laboratory Working Group of the National Kidney Disease Education Program and the International Federation of Clinical Chemistry and Laboratory Medicine Working Group for Standardization of Albumin in Urine recommended desirable and optimal bias goals of ≤13% and ≤7%, respectively, vs. a reference measurement procedure.

These survey results suggest that some measurement procedures can meet these bias goals, but many do not. The survey also reported ACR values. Reference measurement procedure results were not available for urine creatinine but comparison of mean results among different methods in the survey had differences of 17%, 8.8% and 14% at mean concentrations of 55 mg/dL, 69 mg/dL and 89 mg/dL (4.8 mmol/L, 6.1 mmol/L and 7.9 mmol/L), respectively. When both creatinine and albumin were used to calculate the ACR, the differences between the lowest and highest ACR values for all methods combined were 76% at 15 mg/g, 49% at 60 mg/g, and 65% at 237 mg/g. These differences will cause misclassification of risk of kidney disease at the commonly used albuminuria decision values of 30 and 300 mg/g creatinine (3.4 and 34 mg/mmol creatinine).

A reference system is in place for urine creatinine and perhaps needs to be more stringently implemented. However, a reference system does not yet exist for urine albumin and is the focus of this report.

METHODS FOR MEASURING URINE ALBUMIN

To improve the analytical selectivity in the measurement of urine albumin, liquid chromatography mass spectrometry (LC-MS) methods were utilized. A comparison study of one LC-MS method to an immunoturbidimetric method found the comparability between the methodologies greatly improved when both methods employed the same calibrators with the same calibrator value assignments. Mean bias improved from -37.8% to 2.2% using the same calibrators on both platforms. A potential shortcoming of the LC-MS urine albumin method was the lower limit of quantitation of 10-20 mg/L, which is above the level expected in specimens with normal albumin concentrations. Other possibilities that could introduce error with this methodology are the presence of urine albumin fragments containing the N-terminal fragment used in the analysis, which could falsely elevate albumin levels or modification to the N-terminal portion used in analysis that would change the mass, which could falsely lower albumin levels.

In an effort to improve the lower limit of quantitation for urine albumin, a LC-MS/MS method was developed. This method employed proteolysis of urinary proteins to produce peptides of albumin as well as peptides from other proteins present in urine. Large variations in pH (4.5-8) and specific gravity are expected in the urine of patients with or without a kidney abnormality. pH variations could adversely affect the trypsin proteolysis process, which is a critical preanalytic step that occurs prior to LC-MS/MS measurement. Therefore, buffering conditions and dilutions were employed that provide an optimal environment for trypsin proteolysis. Peptides known to be unique to albumin were analyzed and quantitated to represent the quantity of intact albumin. One
of the key components of this method was the incorporation of an internal standard that consisted of a recombinant form of human serum albumin isotopically labeled with $^{15}$N.

The internal standard served dual purpose: 1. to normalize for any differences in the proteolytic processing among specimens; 2. to provide normalization for LC-MS/MS analysis.

Several peptides unique to human serum albumin were quantitated and referenced to a calibration curve. The lower limit of quantitation for the LC-MS/MS measurement procedure was found to be 3.13 mg/L. Method comparison studies have been performed examining commercially available immunoassay platforms to the LC-MS/MS method. The LC-MS/MS measurement procedure was used to perform the comparison study of 16 commercially available measurement procedures previously described.

Potential challenges for a LC-MS/MS method include the possibility of albumin fragments in the urine, post-translational modifications of the unique peptides monitored, or factors that inhibit albumin proteolysis. Further investigation of this technique compared urine albumin concentrations before and after ultrafiltration using a 10 kDa molecular weight cutoff filter where differences in the results were small and suggested minimal signal contribution from fragments of albumin. With the above cautions appropriately addressed in the measurement procedure details, the LC-MS/MS method is a good candidate reference measurement procedure for urine albumin. This method provides the necessary sensitivity to assess urine albumin concentrations <5 mg/L. The ability to quantitate the albumin molecule with a high degree of analytical specificity by using proteotypic peptides of albumin that are not known to be subject to modification and do not appear in other human proteins, provides support for use of the LC-MS/MS method as a reference measurement procedure. To ensure high quality results, the LC-MS/MS measurement procedure requires an isotopically enriched form of albumin as an internal standard. Procedures for making labeled albumin have been described.

**A HIGHER ORDER REFERENCE SYSTEM FOR CALIBRATION TRACEABILITY**

A higher order reference system is needed to enable all measurement procedures to implement common calibration traceability to achieve equivalent results for urine albumin irrespective of the measurement procedure used. A reference system for urine albumin that follows the International Organization for Standardization standard 17511 for calibration traceability hierarchy includes three main components:

1. A pure human albumin primary reference material.
2. A reference measurement procedure.

The National Institute for Standards and Technology (NIST) in the USA is qualifying a recombinant human albumin certified primary reference material expected to be released in 2018 as SRM 2925. SRM 2925 will be a highly purified solid substance intended to be used to prepare calibrators for a mass spectrometry based reference measurement procedure. SRM 2925 is not intended to be used to prepare calibrators for immunoassays. NIST is also preparing an albumin in frozen human urine certified reference material designated SRM 3666 that will include four concentrations intended to be used to establish the metrological traceability of calibration for clinical laboratory measurement procedures, including immunoassays.
SRM 3666 will be value assigned using a NIST reference measurement procedure that is currently in development. The commutability of NIST SRM 3666 will be validated to ensure it is suitable for use as a calibrator for manufacturer’s selected measurement procedures as well as for clinical laboratory measurement procedures. It is not known at this time when either the reference measurement procedure or the SRM 3666 will be available from NIST.

Since SRM 2925 pure albumin will be available soon, development of suitable reference measurement procedures will provide the essential components of a reference system to allow standardized calibration traceability for commercially available clinical laboratory urine albumin immunoassay procedures.

A reference measurement procedure intended for use in a calibration traceability hierarchy for clinical laboratory measurement procedures must have performance characteristics to ensure acceptable uncertainty in values assigned to patient samples used as calibrators in the traceability hierarchy, as described below. In addition, a reference measurement procedure must be operational in at least two sites to

---

Figure 1 Metrologic traceability hierarchy for calibration of urine albumin measurement procedures

| SRM 2925 Human albumin (SI g/L) | Assign value | | Assign value | | Assign value | | Assign value | | Assign value |
|---------------------------------|-------------|-----------|-------------|-----------|-------------|-----------|-------------|-----------|
| SRM 2925 in Solution as Calibrator | Calibrate | | Calibrate | | Calibrate | | Calibrate | | Calibrate |
| Panel of Patient Urine Samples | Assign value | | Assign value | | Assign value | | Assign value | | Assign value |
| Manufacturer’s Working Calibrator (Master Lot) | Calibrate | | Calibrate | | Calibrate | | Calibrate | | Calibrate |
| Manufacturer’s Product Calibrator | Assign value | | Assign value | | Assign value | | Assign value | | Assign value |
| Patient’s Result | | | | | | | | |
validate equivalent performance to qualify for listing by the Joint Committee for Traceability in Laboratory Medicine.

Metrologic traceability of calibration is described in the International Organization for Standardization 17511 standard. Figure 1 shows how the reference system components being developed for urine albumin fit into the traceability hierarchy. NIST SRM 2925 is a pure substance primary reference material that is used with a gravimetric reference measurement procedure to prepare calibrators for an LC-MS/MS reference measurement procedure. The LC-MS/MS reference measurement procedure is used to assign values to a panel of patient’s urine samples that are used as calibrators for a manufacturer’s selected measurement procedure that is used to assign values to the manufacturer’s working, or master lot, calibrator.

In the case of urine albumin, there will be several concentrations of working calibrator used to calibrate the manufacturer’s standing immunoassay measurement procedure. The working calibrators can be prepared as dilutions of a single master lot of working calibrator or as a set of concentrations of working calibrators, with each value assigned by the selected measurement procedure. The manufacturer’s standing measurement procedure is then used to value assign sequential lots or batches of the manufacturer’s product calibrator that is used to calibrate the clinical laboratory measurement procedures. In many cases, the manufacturer’s selected and standing measurement procedures will be the same as the clinical laboratory measurement procedure but operated with a more stringent protocol for items such as maintenance, calibration, replicate measurements, multiple reagent lots and/or instruments to reduce the uncertainty of the value assignment steps. Thus, metrologic traceability is established from patient results to the pure substance primary reference material.

When NIST SRM 3666, albumin in frozen human urine, becomes available it can replace the panel of patient urine samples to simplify the traceability process. In addition, SRM 3666 can be used by clinical laboratories to verify calibration of their immunoassay measurement procedures for urine albumin.

CONCLUSIONS

The need for standardization of urine albumin measurements is clear. Standardization of this measurand will assist in applying uniform clinical decision points for various diseases and conditions based on urine albumin to creatinine ratio values. Standardization of urine albumin measurements requires development of both a certified primary reference material and a reference measurement procedure. LC-MS/MS measurement of albumin-specific peptides after proteolytic digestion under carefully controlled conditions provides a suitable methodology for a reference measurement procedure. When available, these reference system components can be used by immunoassay measurement procedure manufacturers to achieve metrologic traceability of calibration to a common reference system. Availability of a commutable frozen human urine reference material will also be useful as a common calibrator for immunoassays. In addition to standardized metrologic traceability, urine collection and storage conditions influence the suitability of urine albumin measurements and therefore preanalytical processing procedures should be standardized.

REFERENCES


32. Miller WG, Seegmiller JC, Lieske JC, Narva AS, Bachmann LM. Standardization of Urine Albumin Measurements:


